IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	)	Conf. No. 5356
	)	
LANDEGREN et al	)	Examiner:
	)	
Appln. No.: 09/785,657	)	Washington, D.C.
	)	
Filed: February 20, 2001	)	September 20, 2001
	)	
For: METHODS AND KITS FOR PROXIMITY PROBING	)	Atty.Docket: LANDEGREN=1A

RESPONSE TO NOTICE TO COMPLY WITH SEQUENCE LISTING REQUIREMENTS

Honorable Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Notice to Comply included in the Notice to File Missing Parts of Nonprovisional Application dated July 20, 2001, and prior to the examination of the above-described application, please amend the present application as follows:

IN THE SPECIFICATION

Please replace the paragraph beginning at page 11, line 1, with the following rewritten paragraph:

--Fig 10 is a schematic drawing of PDGF-BB bound by two aptamer based proximity-probes, A1c (SEQ ID NO:1) and A2c (SEQ ID NO:2). The aptamer sequence which binds PDGF-BB is shown in close to the protein. The TaqMan probe sequence (reverse complement of SEQ ID NO:3) used in PCR detection is shown. The ligation junction between the proximity-probes is marked with a line between the 3´end of A1c and the 5' end of

A2c. The primer sites are boxed. The ligation template is SEQ ID NO:4.--

Please replace the paragraph beginning at page 13, line 12, with the following rewritten paragraph:

-- Probe A1c :
TACTCAGGGCACTGCAAGCAATTGTGGTCCCAATGGGCTGAGTATGTGGTCTATGTCGTCGT
TCGCTAGTAGTTCCTGGGCTGCAC (SEQ ID NO:1)
Probe A2c :
TCGAGGCGTAGAATTCCCCCGATGCGCGCTGTTCTTACTCAGGGCACTGCAAGCAATTGTGG
TCCCAATGGGCTGAGTAT (SEQ ID NO:2)
Splint template for ligation (6+20):
GGGGGAATTCTACGCCTCGAGTGCAG (SEQ ID NO:3)
Frw primer: ATGTGGTCTATGTCGTCGTTCG (nucleotides 44-65 of SEQ ID NO:1)
Rew primer: TGAGTAAGAACAGCGCGCAT (reverse complement of nucleotides 22-41 of SEQ ID NO:2)
Taq Man probe A1+2c: Fluor-CTGCACTCGAGGCGTAGAATTCCCC-Tamra (reverse complement of SEQ ID NO:3)

PCR cycles: hold 10 min 95, cycle 95 (15 sec) - 60 (1 min) 45 times

IN THE DRAWINGS

Attached is a copy of Figure 10 with proposed revisions marked in red.

IN THE SEQUENCE LISTING

Please enter the attached Sequence Listing, numbered as pages 1-2.